Introduction
Conventional approaches
Role of aspirin in CLL
Treatment of CLL with high risk features
Study agents | Other agents | Disease | Dosage | Clinical trials | No Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Alemtuzumab | High risk | 30 mg | Phase II | 93 | CR:2% | [19] | |
ORR:33% | |||||||
Alemtuzumab | Dexamethasone | Untreated | 30 mg | Phase II | 131 | CR:19/4/3% | [20] |
Relapsed | ORR:98/79/70% | ||||||
Refractory | |||||||
Alemtuzumab | Rituximab | High risk | 30 mg | Phase I | 13 | CR:64% | [21] |
PGG beta glucan | ORR:100% |
New agents
Bendamustine
Study agents | Other agents | Disease | Dose | Trials | No. of Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Bendamustine | chlorambucil | Untreated | 100 mg/m2 | Phase III | 305 | CR:29% | [22] |
ORR:68% | |||||||
Bendamustine | Rituximab | Untreated | 60-100 mg/m2 | Retrospective | 142 | CR:19% | [23] |
High risk | ORR:80% | ||||||
Relapsed | |||||||
Refractory | |||||||
Bendamustine | Rituximab | Untreated | 133.6-165.9 | Retrospective | 217 | CR>19% | [24] |
Prednisone | mg/m2 | ORR>83% | |||||
Bendamustine | Alemtuzumab | Relapsed | 50-70 mg/m2 | Retrospective | 50 | CR:26% | [25] |
Refractory | ORR:70% | ||||||
Bendamustine | Fludarabine | High risk | 20-50 mg/m2 | Phase I/II | 35 | CR/CRi:26% | [26] |
Rituximab | Relapsed | ORR:71% | |||||
Refractory |
Ofatumumab
Study agents | Other agents | Disease | Dosage | Clinical trials | No. of Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Ofatumumab | Untreated | 2000/1000 mg | Phase II | 77 | CR:5/4% | [28] | |
ORR:55/36% | |||||||
Ofatumumab | Lenalidomide | Relapsed | 1000 mg | Phase II | 36 | CR:24% | [31] |
ORR:68% | |||||||
Ofatumumab | Lenalidomide | Relapsed | 2000 mg | Phase II | 17 | ORR:43% | [32] |
Refractory | SD:21% |
Lenalidomide
Study agents | Other agents | Disease | Dosage | Clinical trials | No.of Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Lenalidomide | Relapsed | 5/10/15 mg | Phase II | 95 | CR:2% | [34] | |
Refractory | ORR:79% | ||||||
Lenalidomide | Dexamethasone | Untreated | 5 mg | Phase II | 18 | CR:6% | [35] |
ORR:59% | |||||||
Lenalidomide | Fludarabine | Untreated | 2.5 mg | Phase I/II | 64 | CR:11% | [36] |
Rituximab | Minimally | ORR:63% | |||||
treated |
Ibrutinib
Study agents | Other agents | Disease | Dosage | Clinical trials | No Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Ibrutinib | Relapsed | 420 mg | Phase I | 14 | CR:14% | [38] | |
Refractory | OR:79% | ||||||
Untreated | 420/840 mg | Phase Ib/II | 116 | CR:10/3/0% | [39] | ||
ORR:71/67/50% | |||||||
Ibrutinib | Relapsed/Refractory | ||||||
High risk | |||||||
Ibrutinib | Rituximab | High risk | 420 mg | Phase II | 40 | ORR:85% | [43] |